Celldex Therapeutics
CLDX
167 hedge funds and large institutions have $2.15B invested in Celldex Therapeutics in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 17 closing their positions.
105% more call options, than puts
Call options by funds: $35.1M | Put options by funds: $17.1M
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
55% more capital invested
Capital invested by funds: $1.39B → $2.15B (+$760M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
6% more funds holding
Funds holding: 158 → 167 (+9)
2.62% less ownership
Funds ownership: 104.87% → 102.25% (-2.6%)
13% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$55.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.2M |
| 3 |
Jennison Associates
New York
|
+$10M |
| 4 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
+$9.64M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26.4M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$11.7M |
| 4 |
Goldman Sachs
New York
|
-$7.67M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$5.75M |
CLDX Hedge Fund Activity: Q4 2022 in Review
167 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2022, worth a combined $2.15B — up 55% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CLDX positions and 17 closed out — a net gain of 11 holders — while 49 added to existing stakes and 56 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $55.9M. The largest seller was State Street, cutting an estimated $31.4M.
- 167 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2022, up from 158 in Q3 2022.
- Funds reported $2.15B of Celldex Therapeutics stock for Q4 2022, up 55% quarter-over-quarter.
- 28 funds opened new Celldex Therapeutics positions in Q4 2022 and 17 closed out, a net change of +11 holders.
- The largest Celldex Therapeutics buyer in Q4 2022 was Wellington Management Group, an estimated $55.9M added.
- The largest Celldex Therapeutics seller in Q4 2022 was State Street, an estimated $31.4M sold.
Based on aggregated 13F filings for Q4 2022.